ARDS CONTINUES TO BE PRIMARY CAUSE OF DEATH IN COVID19 , the 45% trial readout is IMMINENT, will the trial be stopped for overwhelming efficacy or will MSB/FDA insist to continue to at least the 60% interim result to make sure the FDA has enough data ? the 60% readout being very close anyway , what will it be shorters ? could get pretty nasty for you to wake up one morning and see the trial stopped and approved for overwhelming efficacy and no chance of a decentring vote doing a job on MSB.
Remestemcell- L the block buster therapy for the critically ill.
Ann: Phase 3 Trial in COVID-19 ARDS Surpasses 50% Enrollment, page-120
-
- There are more pages in this discussion • 326 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add MSB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.13 |
Change
-0.025(2.17%) |
Mkt cap ! $1.284B | |||
| Open | High | Low | Value | Volume |
| $1.15 | $1.16 | $1.11 | $7.363M | 6.488M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 5 | 94863 | $1.13 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.13 | 5000 | 2 |
View Market Depth
| Last trade - 16.10pm 26/07/2024 (20 minute delay) ? |
| MSB (ASX) Chart |